Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Recognized by America's Top Doctors for 2017
Recognized in Philadelphia magazine's annual Top Docs issues for 2018 and 2019
Medical Oncology, 1998
Abramson Cancer Center
Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology
Esserman L, Yeee D, DeMichele A, Yau C, Issacs C, Symmans WF, Albain K, Chen Yunn-yi, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocoo A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal I, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Yang S, Adams A, Chein AJ, Forero-Torres T, Stringer-Reasor E, Wallace AM, Pusztai L, Boughry JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Korde L, Nanda R, Northfelt DW, Khan QJ, Visvcusi RK, Euhus DM, Edison KK, Chi AY, Kemmer K, Wood WC, Park JW, Liu MC, Olopade O, Layland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, van 't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paolini M, Clennel JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Beery DA: Disease-free survival correlates with pathologic complete response in the adaptively randomized I-SPY2 trial of stage 2/3 breast cancer The Lancet : 2020.
McDonald E, Doot RK, Carlin SD, Pantel A, Shah PD, Clark AS, Desai H, Kelly G, Young AJ, Pryma DA, Farewell MD, Nayak A, Lee H, Schubert EK, Makvandi M, Xiober A, Tchou J, DeMichele A, Feldman M, Domchek SM, Mach RH, Maxwell KN, Manoff: PARP Imaging in Breast Bancer JAMA Oncology : 2020.
Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, Clark A, Bradbury A, Matro J, Adusumalli S, Carver JR, Ky B.: Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy JACC: Cardiovascular Imaging
Schmitz KH, Troxel, AB, Dean LT, DeMichele A, Brown JC, Sturgeon K, Zhang Z, Evangelisti M, Spinelli B, Kallan MJ, Denlinger C, Cheville A, Winkels RM, Chodosh L, Sarwer DB: Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer–Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors JAMA Oncology : 2019.
Kawut SM, Pinder D, Al-Naamani N, McCormick A, Palevsky HI, Fritz J, Smith KA, Mazurek JA, Doyle MF, MacLean MR, DeMichele A, Mankoff DA.: Fulvestrant for the Treatment of Pulmonary Arterial Hypertension Annals of the American Thoracic Society : 2019.
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M.: Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer Journal of Clinical Oncology : 2019.
Martei YM, Grover S, Bilker WB, Monare B, Setlhako DI, Ralefala TB, Manshimba P, Gross R, Shulman LN, DeMichele A: Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting Journal of Global Oncology : 2019.
Clark AS, McAndrew NP, Troxel A, Feldman M, Lal P, Rosen M, Burrell J, Redlinger C, Gallgher M, Bradbury AR, Domchek SM, Fox KR, O'Dwyer PJ, DeMichele, AM: Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in
Advanced Breast Cancer Clinical Cancer Research Epub ahead of print : 2019.
Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A, Chien JA, Forero-Torres A, Ellis E, Han H, Clark AS, Albain K, Boughey J, Jaskowiak N, Elias A, Isaacas C, Kemmer K, Helsten T, Maure M, Stinger-Reasor E, Parker C, Lee M, Haddad T, Cohen R, Asare S, Wilson A, Hirst G, Singhrao R, Asare A, Matthews J, Berry S, Schwab R, Symmans W, van't Veer L, Yee D, DeMichele A, Hylton N, Oerlmutter J, Rugo H, Berry D, Esserman L: Pembrolizumab for Early-Stage, High-Risk, HER2-Negative Breast
Cancer: Results from the I-SPY2 Trial New England Journal of Medicine : 2019.
Demissei BG, Finkelman B, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury A, Carver JR, Upshaw J, Armenian SH, Liu P, Ky B: Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy Cancer In press : 2019.
Division of Hematology Oncology Perelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-1533400 Civic Center Boulevard
Phone: (215) 349-5730
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.